Seattle Genetics Announces More Than 20 Presentations At American Society of Hematology 2015 Highlighting Progress With Broad ADCETRIS (Brentuximab Vedotin) Development Plan And Multiple Antibody-Drug Conjugate (ADC) Pipeline Programs

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that a record number of abstracts were accepted for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015, including the following:

Help employers find you! Check out all the jobs and post your resume.